PSTV vs. NURO, OSA, VAPO, VVOS, INBS, BTCY, PETV, AVGR, TMDIF, and MBOT
Should you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include NeuroMetrix (NURO), ProSomnus (OSA), Vapotherm (VAPO), Vivos Therapeutics (VVOS), Intelligent Bio Solutions (INBS), Biotricity (BTCY), PetVivo (PETV), Avinger (AVGR), Titan Medical (TMDIF), and Microbot Medical (MBOT). These companies are all part of the "surgical & medical instruments" industry.
NeuroMetrix (NASDAQ:NURO) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 4.4% of NeuroMetrix shares are owned by company insiders. Comparatively, 2.3% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Plus Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 244.83%. Given NeuroMetrix's higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than NeuroMetrix.
NeuroMetrix has a net margin of -110.64% compared to NeuroMetrix's net margin of -271.04%. Plus Therapeutics' return on equity of -31.31% beat NeuroMetrix's return on equity.
In the previous week, Plus Therapeutics had 8 more articles in the media than NeuroMetrix. MarketBeat recorded 12 mentions for Plus Therapeutics and 4 mentions for NeuroMetrix. NeuroMetrix's average media sentiment score of 0.61 beat Plus Therapeutics' score of 0.30 indicating that Plus Therapeutics is being referred to more favorably in the news media.
NeuroMetrix has higher revenue and earnings than Plus Therapeutics. NeuroMetrix is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.
NeuroMetrix received 221 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 61.87% of users gave NeuroMetrix an outperform vote while only 60.58% of users gave Plus Therapeutics an outperform vote.
NeuroMetrix has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Summary
NeuroMetrix beats Plus Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Plus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Plus Therapeutics Competitors List
Related Companies and Tools
